^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    volrustomig (MEDI5752)

    i
    Other names: MEDI5752, MEDI-5752, MEDI 5752
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    1m
    MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC (clinicaltrials.gov)
    P1, N=17, Completed, Presage Biosciences | Recruiting --> Completed | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    2ms
    eVOLVE-HNSCC: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P3, N=1145, Recruiting, AstraZeneca | Trial completion date: Sep 2030 --> Feb 2031 | Trial primary completion date: Apr 2028 --> Apr 2030
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    volrustomig (MEDI5752)
    2ms
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=861, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2027 --> Nov 2028
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    3ms
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Presage Biosciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    3ms
    FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=400, Active, not recruiting, MedImmune LLC | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • volrustomig (MEDI5752)
    3ms
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    3ms
    D798MC00002: Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors (2025-523947-36-00)
    P1/2, N=42, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)
    3ms
    DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)
    P1, N=304, Recruiting, AstraZeneca | N=33 --> 304
    Enrollment change • IO biomarker
    |
    HER-2 overexpression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    4ms
    Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) (2024-511857-23-00)
    P1/2, N=43, Completed, Assistance Publique Hopitaux De Paris | Not yet recruiting --> Completed
    Trial completion • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    4ms
    MONAMI: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • dMMR • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    4ms
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    5ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=257, Recruiting, AstraZeneca | N=110 --> 257
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)